UNSPSC 51332302: Milenperone

This classification denotes an anxiolytic with the molecular formula C22H23CLFN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9GC5JKP4BD chemically known as 2h-benzimidazol-2-one, 5-chloro-1-(3-(4-(4-fluorobenzoyl)-1-piperidinyl)propyl)-1,3-dihydro- but generally known as milenperone, which bears US NIH Compound Identifier 65489. European Medicines Agency schedules Milenperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08962MIG.

UNSPSC 51332302 Milenperone is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. Recent solicitations show state and local bodies buying these items through competitive bidding processes, cooperative purchasing agreements, and requests for information designed to establish direct-to-manufacturer relationships and multi-vendor supply contracts. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; Seminole County, Florida and the Texas Health and Human Services Commission appear in current procurement activity, as does the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which administers contracts for participating state and local facilities across multiple jurisdictions including Oregon.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County issued an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract includes a two-year initial term with one-year renewal option and compliance with E-Verify, drug-free workplace certification, and potential FEMA-related federal environmental regulations. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting capacity and outcomes-based pricing models outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to supply authorized wholesalers effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and administrative fee acceptance; vendors must maintain relationships with at least two of three specified wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements.